Aberdeen Group plc lessened its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 78.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 80,319 shares of the company’s stock after selling 292,447 shares during the quarter. Aberdeen Group plc’s holdings in Syndax Pharmaceuticals were worth $1,510,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Allworth Financial LP acquired a new position in shares of Syndax Pharmaceuticals during the second quarter worth $26,000. Sterling Capital Management LLC boosted its holdings in shares of Syndax Pharmaceuticals by 846.6% during the 3rd quarter. Sterling Capital Management LLC now owns 2,963 shares of the company’s stock valued at $56,000 after acquiring an additional 2,650 shares in the last quarter. Nykredit A S bought a new stake in Syndax Pharmaceuticals during the 2nd quarter worth $72,000. Integrated Wealth Concepts LLC bought a new stake in Syndax Pharmaceuticals during the 2nd quarter worth $73,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Syndax Pharmaceuticals in the 3rd quarter worth about $86,000.
Syndax Pharmaceuticals Stock Down 4.4%
NASDAQ SNDX opened at $8.73 on Friday. The company has a current ratio of 4.69, a quick ratio of 4.37 and a debt-to-equity ratio of 38.95. Syndax Pharmaceuticals, Inc. has a one year low of $8.41 and a one year high of $25.59. The business’s fifty day moving average is $14.22 and its 200-day moving average is $19.44.
Wall Street Analysts Forecast Growth
A number of analysts recently weighed in on the company. Mizuho set a $43.00 price objective on Syndax Pharmaceuticals in a report on Tuesday, November 3rd. Weiss Ratings raised Syndax Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, November 3rd. UBS Group reduced their price target on Syndax Pharmaceuticals from $33.00 to $31.00 and set a “buy” rating on the stock in a research report on Friday. Bank of America reiterated a “buy” rating on shares of Syndax Pharmaceuticals in a research report on Wednesday, August 5th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $35.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday, September 29th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $41.40.
View Our Latest Stock Analysis on SNDX
Insiders Place Their Bets
In related news, Director Dennis Podlesak sold 8,000 shares of the firm’s stock in a transaction dated Thursday, October 29th. The stock was sold at an average price of $14.21, for a total value of $113,680.00. Following the sale, the director directly owned 239,763 shares of the company’s stock, valued at $3,407,032.23. This trade represents a 3.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.80% of the stock is owned by corporate insiders.
Syndax Pharmaceuticals Profile
Syndax Pharmaceuticals is a biotechnology company focused on developing and commercializing medicines for cancer and related serious diseases. Its research programs include therapies that target cancer-driving pathways, including menin and the colony-stimulating factor 1 receptor (CSF-1R). The company’s medicines include Revuforj (revumenib), approved in the United States for certain adults and children aged one year and older with relapsed or refractory acute leukemia involving a KMT2A translocation.
Read More
- Five stocks we like better than Syndax Pharmaceuticals
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Want to see what other hedge funds are holding SNDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report).
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
